GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » E10

Daiichinkyo Co (Daiichinkyo Co) E10 : $0.43 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Daiichinkyo Co's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.129. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.43 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Daiichinkyo Co's average E10 Growth Rate was 16.00% per year. During the past 3 years, the average E10 Growth Rate was 10.40% per year. During the past 5 years, the average E10 Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Daiichinkyo Co was 10.40% per year. The lowest was -11.50% per year. And the median was 6.20% per year.

As of today (2024-04-28), Daiichinkyo Co's current stock price is $32.20. Daiichinkyo Co's E10 for the quarter that ended in Mar. 2024 was $0.43. Daiichinkyo Co's Shiller PE Ratio of today is 74.88.

During the past 13 years, the highest Shiller PE Ratio of Daiichinkyo Co was 90.32. The lowest was 8.79. And the median was 53.54.


Daiichinkyo Co E10 Historical Data

The historical data trend for Daiichinkyo Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co E10 Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.43 0.41 0.42 0.43

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.40 0.39 0.43 0.43

Competitive Comparison of Daiichinkyo Co's E10

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Shiller PE Ratio falls into.



Daiichinkyo Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Daiichinkyo Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.129/107.2000*107.2000
=0.129

Current CPI (Mar. 2024) = 107.2000.

Daiichinkyo Co Quarterly Data

per share eps CPI Adj_EPS
201406 0.093 98.000 0.102
201409 0.133 98.500 0.145
201412 0.206 97.900 0.226
201503 0.863 97.900 0.945
201506 0.134 98.400 0.146
201509 0.144 98.500 0.157
201512 0.160 98.100 0.175
201603 -0.120 97.900 -0.131
201606 0.141 98.100 0.154
201609 0.089 98.000 0.097
201612 0.169 98.400 0.184
201703 -0.151 98.100 -0.165
201706 0.132 98.500 0.144
201709 0.023 98.800 0.025
201712 0.171 99.400 0.184
201803 -0.057 99.200 -0.062
201806 0.112 99.200 0.121
201809 0.092 99.900 0.099
201812 0.159 99.700 0.171
201903 0.068 99.700 0.073
201906 0.206 99.800 0.221
201909 0.101 100.100 0.108
201912 0.329 100.500 0.351
202003 -0.025 100.300 -0.027
202006 0.152 99.900 0.163
202009 0.096 99.900 0.103
202012 0.120 99.300 0.130
202103 0.002 99.900 0.002
202106 0.167 99.500 0.180
202109 0.129 100.100 0.138
202112 0.146 100.100 0.156
202203 -0.120 101.100 -0.127
202206 0.073 101.800 0.077
202209 0.144 103.100 0.150
202212 0.110 104.100 0.113
202303 0.088 104.400 0.090
202306 0.210 105.200 0.214
202309 0.141 106.200 0.142
202312 0.241 106.800 0.242
202403 0.129 107.200 0.129

Add all the adjusted EPS together and divide 10 will get our e10.


Daiichinkyo Co  (OTCPK:DSNKY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Daiichinkyo Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=32.20/0.43
=74.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Daiichinkyo Co was 90.32. The lowest was 8.79. And the median was 53.54.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Daiichinkyo Co E10 Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.